Prime Medicine (PRME) Accounts Payables (2021 - 2026)

Prime Medicine (PRME) has 6 years of Accounts Payables data on file, last reported at $12.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 22.94% year-over-year to $12.3 million; the trailing twelve-month figure through Mar 2026 stood at $12.3 million (up 22.94% YoY), and the FY2025 full-year result was $8.9 million, down 21.71% from the prior year.
• Accounts Payables for Q1 2026 stood at $12.3 million, up from $8.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $19.5 million in Q4 2023 and bottomed at $4.1 million in Q3 2022.
• The 5-year median for Accounts Payables is $8.9 million (2025), against an average of $8.7 million.
• The widest annual swing landed in 2023, when Accounts Payables soared 350.99%; it then plunged 61.56% in 2024.
• A 5-year view of Accounts Payables shows it stood at $4.3 million in 2022, then jumped by 350.99% to $19.5 million in 2023, then sank by 41.9% to $11.4 million in 2024, then decreased by 21.71% to $8.9 million in 2025, then surged by 38.69% to $12.3 million in 2026.
• The last three Accounts Payables figures came in at $12.3 million (Q1 2026), $8.9 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.

Peer Comparison